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Secondary amyloidosis typically occurs in chronic disease states in which there
is presumed to be persistent antigenic stimulation. Therefore, it has long been
hypothesized that secondary amyloidosis might be the result of an abnormality
in antibody production. The finding that amyloid fibril proteins in primary
amyloidosis are composed mainly of fragments of immunoglobulin light chains
strengthened the argument that immunoglobulin abnormalities were involved in
amyloidogenesis (1). However, the deposits in secondary amyloidosis have been
shown to be largely composed ofa small molecular weight protein (8,400 daltons)
which bears no relationship to any known immunoglobulin molecule (2, 3). This
protein (AA) is felt to be derived from a serum alpha globulin (SAA) (mol wt
approx . 100,000) which has been shown to be elevated in amyloidosis and
probably is present in small amounts in all normal sera (4, 5). The function of
this protein (SAA) and its role in amyloidogenesis are the subject of this report.
The availability of an experimental model of amyloidosis in the mouse which
appears to be analogous to human secondary amyloidosis (6) has allowed us to
demonstrate that SAA suppresses antibody formation.
Materials and Methods
Mouse Sera.
￿
8-wk old female CBA/Jmice (Jackson Laboratories, BarHarbor, Maine) were made
amyloidotic by 21 daily injections of 0.5 ml of 10% casein as previously described (6). The animals
were bled 3 days afterthelast casein injection. Normal 10- to 12-wk old female CBA/Jmice were bled
for control serum.
Preparation of Antiserum.
￿
Amyloidfibrils, isolated from the spleens of amyloidotic CBA/J mice
as previously described (7), were solubilized in 4 molar guanidine and fractionated on Sephadex
G100. The major retarded fraction (protein AA) was isolated and used to immunize New Zealand
white rabbits by serial injections in complete Freund's adjuvant.
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Spleen Cell Cultures.
￿
The Mishell-Dutton culture system was used for antibody stimulation in
vitro (8). 10- to 12-wk old CBA/J mice were immunized with 0.1 cc of a 10% suspension of sheep red
blood cells (SRBC) (Colorado Serum Company, Denver, Colo.). 3 days later the mice were sacrificed
andsterile spleen cell suspensions made in Eagle's minimal essential media (MEM) which hadbeen
supplemented with 10% fetal bovine serum (Reheis Chemical Company, Chicago, Ill.). 1 ml of
cell suspension (1.5 x 10' cells) was placed in a 30 mm petri dish with varying amounts of either
normal mouse serum or amyloid mouse serum and50 /A of 1% SRBC as antigen . On the fourth daythe
cells were harvested and SRBC antibody-forming cells determined using the Jerne hemolytic plaque
assay. Each experimental andcontrol group consisted of 6-10 separate cultures. Viability testing was
done using trypan blue dye exclusion. To measure indirect plaque-forming cells (PFC) two sets of
agar plates were prepared for each sample. In one set direct PFC were developed with guinea pig
complement. The second set was incubated with rabbit antimouse IgG and complement. Indirect or
7S PFC were calculated as the difference between total PFC and direct PFC.
Amyloid serum was absorbed by incubating with an equal volume of rabbit anti-AA serum for 48 h
and centrifuging at 18,000 g for 1 h. The data were analysed statistically using the Student's t test,
and are expressed as geometric mean t standard error. For clarity some data are expressed as
response index (ratio of PFC/culture of experimental to PFC/culture of controls) .
Results
Initial experiments were done to determine if serum from amyloidotic mice
would suppress antibody formation in vitro. 50 p,1 of amyloidotic serum were
added to each experimental culture (5% vol/vol) while equal volumes of normal
mouse serum (NMS) were added to cultures as controls . The amyloidotic serum
caused significant suppression of direct (19S) PFC in three separate experiments
(Table I). Since the spleen cell donors were primed before culture, it is possible
that some 7S PFC were produced which were not suppressed. Therefore the
experiment was repeated using an indirect (7S) PFC assay. Again 50 Al of
amyloidotic serum suppressed 90% of the control response (259 PFC for NMS
versus 26 PFC for amyloid serum P < 0.025) . Percent ofviable cells after 4 days
in culture as determined by trypan blue dye exclusion was the same in the
cultures incubated with amyloidotic serum as in control cultures (60%) . This
excludes a nonspecific cytotoxic effect on cultured lymphocytes as the cause of
suppression.
The suppression of antibody response to SRBC was proportional to the amount
of amyloidotic serum added to the culture and ranged from 99.8% suppression at
a concentration of 10% serum down to 69% at 1% serum (Table II). Significant
suppression was achieved with as little as 1% serum in the culture.
To determine if the suppressive factor was serum A protein (SAA), specific
rabbit antiserum to murine amyloid protein AA was used to absorb the amyloid
serum. This antiserum, which was produced to the tissue protein AA, showed a
line of identity between AA and amyloid mouse serum by double diffusion in
TABLE I
Inhibition of In Vitro Antibody Response by Amyloid Serum
Exp.
Normal mouse
serum (5%)
PFC/culture t SE
Amyloid mouse
serum (5%)
PFC/culture t SE
Inhibition
%
P
1 2,456t 35 37 t 13 98 <0.001
2 1,135t 321 48 f 18 96 <0.025
3 4,366f 551 832 t 83 81 <0.005238
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TABLE II
Dose-Response Effect of Amyloid Serum on Antibody Response to
SRBC
Normal mouse serum
Amyloid mouse serum
agar. The amyloid serum was also absorbed with normal rabbit serum as a
control. The results (Fig. 1) show that amyloid mouse serum (AMS) suppressed
PFC response to 20% of normal mouse serum controls (P < 0.05); and after
absorption with normal rabbit serum (NRS), the degree ofsuppression was still
highly significant (P < 0.005). Absorption of the AMS with anti-AA reversed the
suppression (P < 0.005 comparing PFC response of absorbed and unabsorbed
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￿
Reversal of amyloid serum suppression of PFC by absorption with rabbit antiamyloid
AA. Results expressed as response index (ratio of PFC/culture in experimental to PFC/culture
in normal mouse serum controls) . Amyloid serum suppresses significantly (P < 0.05) . After
absorption with normal rabbit serum, amyloid serum still suppresses (P < 0.005). Absorption
with rabbit anti-AA reverses suppression of amyloid serum.
Concn. Direct PFC/
culture t SE Inhibition P
5 6,431 t 602
0.5 3,108 f 375 52 <0.1
1.0 1,974 t 139 69 <0.005
2.0 720 t 150 89 <0.001
5.0 326 f 48 95 <0.005
10.0 1516 99.8 <0.001BENSON ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
239
AMS). Rabbit anti-AA when added to control cultures alone had no stimulatory
effect upon PFC response to SRBC.
Since normal mouse serum has previously been shown to have a suppressive
effect on antibody formation (9), four separate batches of normal CBA/J sera
were added to cultures and compared to cultures having only fetal calfserum. We
found that 5% normal mouse serum suppressed between 30% and 50% of the
normal SRBC response in three out of four batches of serum. Since we have
demonstrated trace amounts ofSAA in normal mouse serum by radioimmunoas-
say,' it appeared possible that SAA could account for the suppressive effect of
normal mouse serum. Therefore, we absorbed normal mouse serum with specific
anti-AA and added the absorbed serum to spleen cell cultures (Fig. 2).
Absorption with anti-AA removed the suppressive effect ofnormal mouse serum.
Control cultures containing both normal rabbit serum (5%) and NMS (5%) did
not show any reversal of PFC suppression.
Discussion
Casein-induced amyloidosis in the mouse and guinea pig appears to be
analogous to human secondary amyloidosis (7, 10). Allhave as amajor component
of the fibril deposits a small molecular weight protein (AA). The entire sequence
of 76 amino acids is known for the human protein (3). The guinea pig-derived
protein has been sequenced to 25 residues and is homologous to the human AA
except for a 5 amino acid peptide at the amino terminus .
In all three species there is a circulating alpha globulin which immunologically
cross reacts with antiserum to the autologous tissue protein AA but in each case
is speciesspecific. In the human this alpha globulin (SAA) which is believed to be
a precursor ofthe fibril protein has a mol wt of approximately 100,000 (3, 5). It is
present in small amounts in all normal sera and is markedly elevated in
secondary amyloidosis, cancer, and many acute and chronic inflammatory
diseases (4, 5, 11). Sera from amyloidotic mice have elevated levels of SAA as
shown by Ouchterlony analysis and radioimmunoassay (12, footnote 1). Normal
CBA/J serum has low levels ofSAA by radioimmunoassay. No specific functional
activity of this circulating protein has been previously described.
The present studies clearly show that serum from amyloidotic mice markedly
suppresses in vitro antibody response to SRBC. This suppression is reversed by
absorbing the serum with rabbit antiserum specific for murine amyloid protein
AA but is not reversed by normal rabbit serum. Thus the suppressive factor in
amyloidotic serum would appear to be SAA. This is the first demonstration of an
immune suppressive function for amyloid protein SAA.
Veit and Michael have previously shown that mouse serum suppresses the
primary immune response to SRBC (9, 13). This suppression was greater in
serum from immunized mice . The possibitity exists that this suppression is
related to SAA, and is supported by the demonstration that anti-AA reverses the
suppression of normal mouse serum in this study.
The mechanisms involved in immune suppression by SAA are not clear.
Antibody response to SRBC is thymus-dependent and, therefore, suppression
'Benson, M.D. Manuscript in preparation.240
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￿
Reversal of NMS suppression of PFC by absorption with antiamyloid AA. Results
expressed as response index (ratio of PFC/culture of experimental to PFC/culture in fetal calf
serum) .
could be either affected upon thymus or bone marrow-derived cells. If SAA is the
same factor that has been studied by Veit and Michael, it would appear from
their data that it suppresses T cells and not B cells directly. Even so, the SAA
could function by direct action upon the antigen-sensitized cells or through
suppressor cells. It would appear that the SAA is a nonspecific inhibitor of
antibody response . Whether it regulates other processes of the immune system,
such a cell-mediated immunity, has not yet been determined.
Within the past few years a large amount of data have been accumulated
which suggest abnormalities in immune functions in casein-treated animals (14,
15) . Whether any of these findings are related to SAA is not yet known. The
present studies tend to suggest that SAA is a normal hormonal factor which is
elevated in response to antigenic stimulation. Therefore, there may be no
abnormality in immune regulation but just the normal control of antibody
response. In secondary amyloidosis the abnormality may be only the inability of
the body to deal with the sustained high levels of SAA caused by chronic
antigenic stimulation.
Summary
Serum from CBA/J mice made amyloidotic by chronic casein injections has
been shown to suppress in vitro antibody response to SRBC . Similarsuppressionwas also found with normal mouse serum but to a much lesser degree. This
suppressive activity of both amyloidotic serum and normal serum was removed
by absorption of the sera with antiserum to protein AA, the major constituent of
casein-induced (secondary) amyloid fibrils. This antiserum to the amyloid fibril
protein AA (mol wt 8,400 daltons) detects an immunologically cross-reacting
serum alpha globulin (SAA) (mol wt approx. 100,000) . It is postulated that the
serum factor (SAA) is a regulator of antibody response and may be present in
elevated amounts as the result of chronic antigenic stimulation.
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